CIK 0001855175 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Contineum Therapeutics, Inc.
Sign in to watch- Ticker
- CTNM
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 271467257
- Phone
- (858) 333-5280
- Business address
- 3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO, CA, 92121
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $41,142
- in 1 filing, $41K under 10b5-1 plans
Net −$41,142. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-30 | Lorrain Daniel S. Chief Scientific Officer | Sale 10b5-1 | −28,826 | $16.04 | $462K | 139,372 |
| 2026-06-30 | Lorrain Daniel S. Chief Scientific Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −28,826 | 38,480 | ||
| 2026-06-30 | Watkins Tim CMO & Head of Development | Option exercise 10b5-1 | +10,833 | $4.50 | $49K | 19,794 |
| 2026-06-30 | Watkins Tim CMO & Head of Development | Sale 10b5-1 | −10,833 | $16.02 | $174K | 8,961 |
| 2026-06-30 | Watkins Tim CMO & Head of Development | Option exercise · Stock Option (right to buy) 10b5-1 | −10,833 | 238,334 | ||
| 2026-06-30 | Stengone Carmine N. CEO and President | Option exercise 10b5-1 | +7,500 | $1.01 | $8K | 24,717 |
| 2026-06-30 | Stengone Carmine N. CEO and President | Option exercise 10b5-1 | +2,500 | $1.26 | $3K | 27,217 |
| 2026-06-30 | Stengone Carmine N. CEO and President | Sale 10b5-1 | −10,000 | $16.01 | $160K | 17,217 |
| 2026-06-30 | Stengone Carmine N. CEO and President | Option exercise · Stock Option (right to buy) 10b5-1 | −7,500 | 281,930 | ||
| 2026-06-30 | Stengone Carmine N. CEO and President | Option exercise · Stock Option (right to buy) 10b5-1 | −2,500 | 118,417 | ||
| 2026-06-26 | Miralles Gines Diego Director | Grant or award · Stock Option (right to buy) | +19,000 | 19,000 | ||
| 2026-06-26 | Lyons-Williams Lori Director | Grant or award · Stock Option (right to buy) | +19,000 | 19,000 | ||
| 2026-06-26 | Ware Olivia C Director | Grant or award · Stock Option (right to buy) | +19,000 | 19,000 | ||
| 2026-06-26 | Schimmelpennink Evert B. Director | Grant or award · Stock Option (right to buy) | +19,000 | 19,000 | ||
| 2026-06-26 | Ignelzi Troy A. Director | Grant or award · Stock Option (right to buy) | +19,000 | 19,000 | ||
| 2026-06-26 | Brady Todd R. Director | Grant or award · Stock Option (right to buy) | +19,000 | 19,000 | ||
| 2026-06-26 | Boyce Sarah Director | Grant or award · Stock Option (right to buy) | +19,000 | 19,000 | ||
| 2026-06-01 | Lorrain Daniel S. Chief Scientific Officer | Sale 10b5-1 | −4,170 | $13.16 | $55K | 139,372 |
| 2026-05-01 | Lorrain Daniel S. Chief Scientific Officer | Sale 10b5-1 | −3,870 | $13.06 | $51K | 143,842 |
| 2026-05-01 | Lorrain Daniel S. Chief Scientific Officer | Sale 10b5-1 | −300 | $13.84 | $4K | 143,542 |
Page 2 of 7 · 139 trades